Table 1.

Allelic and genotypic frequencies and risks for lung cancer in Caucasians

Genes (reference no.)Major/minor alleleMinor allele frequencyCommon homozygote (n)Heterozygote (n)Rare homozygote (n)Heterozygote and rare homozygote (n)HWE P
CCND1 G870A (rs603965)G/ACase0.473686382849220.81
Control0.443696452278720.06
OR (95% CI)*Reference0.99 (0.82-1.18)1.26 (1.03-1.53)1.06 (0.89-1.25)
p53 Intron 3 (16 bp deletion)Deletion/—Case0.141,044348203680.14
Control0.131,036301263270.45
OR (95% CI)Reference1.15 (0.97-1.38)0.77 (0.42-1.38)1.12 (0.94-1.33)
p53 R72P (rs1042522)G/CCase0.25756492925840.33
Control0.26702481905710.54
OR (95% CI)Reference0.95 (0.81-1.12)0.93 (0.68-1.27)0.95 (0.81-1.11)
p53 Intron 6 (rs1625895)G/ACase0.15956347213680.10
Control0.12960260252850.14
OR (95% CI)Reference1.34 (1.11-1.61)0.83 (0.46-1.49)1.29 (1.08-1.55)
CDK4 promoter (rs2072052)A/CCase0.31287252613130.61
Control0.30294248583060.59
OR (95% CI)Reference1.04 (0.82-1.33)1.06 (0.71-1.58)1.04 (0.83-1.32)
CDK6 3′ UTR (rs42309)G/TCase0.27321238412790.73
Control0.25342233382710.84
OR (95% CI)Reference1.1 (0.87-1.40)1.22 (0.76-1.96)1.12 (0.89-1.41)
p27 5′ UTR (rs34330)C/TCase0.28324222402620.81
Control0.22369207332400.58
OR (95% CI)Reference1.25 (0.98-1.59)1.39 (0.85-2.27)1.27 (1.01-1.60)
p21 3′ UTR (rs1059234)C/TCase0.07539832850.76
Control0.07541831840.35
OR (95% CI)Reference0.96 (0.69-1.34)1.78 (0.16-19.7)0.97 (0.70-1.35)
p21 S31R (rs1801270)C/ACase0.07536841850.35
Control0.07535861870.35
OR (95% CI)Reference0.96 (0.69-1.33)0.90 (0.06-14.5)0.95 (0.69-1.32)
STK15 F31I (rs2273535)A/TCase0.20692373364090.09
Control0.22594320513710.36
OR (95% CI)Reference1.03 (0.85-1.24)0.58 (0.37-0.90)0.97 (0.81-1.16)
STK15 I57V (rs1047972)G/ACase0.15916321263470.73
Control0.16819304313350.66
OR (95% CI)Reference0.95 (0.79-1.14)0.74 (0.44-1.27)0.93 (0.78-1.11)
  • Abbreviation: HWE, Hardy-Weinberg equilibrium.

  • * Adjusted for age, gender, smoking status, and pack-years.